Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janna Minehart

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of the National Cancer Institute|March 17, 2018
Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune ResponsesVivek Murthy, Janna Minehart, Daniel H Sterman
Current Oncology (Toronto, Ont.)|March 26, 2025
Extramedullary Multiple Myeloma: Challenges and OpportunitiesMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2015
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALLMatthew C Stubbs, Wonil Kim, Megan Bariteau, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2019
Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot studyVivek Murthy, Daniel P Katzman, Jun-Chieh J Tsay, et al.
Blood Advances|September 30, 2018
Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by <i>Mll-Af4</i> and activated <i>Ras</i>S Haihua Chu, Evelyn J Song, Jonathan R Chabon, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of the National Cancer Institute|March 17, 2018
Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune ResponsesVivek Murthy, Janna Minehart, Daniel H Sterman
Current Oncology (Toronto, Ont.)|March 26, 2025
Extramedullary Multiple Myeloma: Challenges and OpportunitiesMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2015
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALLMatthew C Stubbs, Wonil Kim, Megan Bariteau, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2019
Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot studyVivek Murthy, Daniel P Katzman, Jun-Chieh J Tsay, et al.
Blood Advances|September 30, 2018
Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by <i>Mll-Af4</i> and activated <i>Ras</i>S Haihua Chu, Evelyn J Song, Jonathan R Chabon, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Pageof 1